Exploring the medical uses of recreational drugs mcgilltribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mcgilltribune.com Daily Mail and Mail on Sunday newspapers.
/CNW/ - Diamond Therapeutics Inc. ("Diamond"), a leading psychedelic drug development company focused on low-dose therapies for mental health, has entered into.
Share this article
TORONTO, Feb. 4, 2021 /PRNewswire/ - Diamond Therapeutics Inc. (
Diamond ), a leading psychedelic drug development company focused on low-dose therapies for mental health, has entered into an agreement with McGill University for the exclusive use of Dr. Gabriella Gobbi s groundbreaking studies with lysergic acid diethylamide (LSD), its mechanism of action on the brain, and its potential for use at low doses in the treatment of mental health disorders.
The agreement provides Diamond with access to the technology, data and intellectual property developed by Dr. Gobbi and postdoctoral fellow Danilo De Gregorio, PharmD, Ph.D. and published in the Proceedings of the National Academy of Sciences of the United States of America. The work investigates for the first time the mechanism of action behind LSD s effect on social interactions. The findings suggest that psychedelics could play a role in treating diseases characterized by social impairment, such as autism spe
Mouse study reveals a mechanism of LSD on prosocial behavior
Written by Timothy Huzar on January 30, 2021 Fact checked by Alexandra Sanfins, Ph.D.
Scientists have identified a biological mechanism that accounts for the prosocial behavior associated with repeated microdoses of LSD in mice.
microgen/Getty Images
In a new mouse study, scientists have identified a mechanism that may help explain the prosocial behavior effects of microdoses of lysergic acid diethylamide (LSD).
The study, which appears in the
LSD
In recent years, microdosing, which refers to consuming tiny amounts of psychedelic substances, has been increasingly debated. According to an article in the journal
Date Time
LSD may offer viable treatment for certain mental disorders
McGill study a step in understanding the mechanism of psychedelics’ impact on brain and potential for therapeutic use
Researchers from McGill University have discovered, for the first time, one of the possible mechanisms that contributes to the ability of lysergic acid diethylamide (LSD) to increase social interaction. The findings, which could help unlock potential therapeutic applications in treating certain psychiatric diseases, including anxiety and alcohol use disorders, are published in the journal PNAS.
Psychedelic drugs, including LSD, were popular in the 1970s and have been gaining popularity over the past decade, with reports of young professionals claiming to regularly take small non-hallucinogenic micro-doses of LSD to boost their productivity and creativity and to increase their empathy. The mechanism of action of LSD on the brain, however, has remained a mystery.